Autologous Conditioned Plasma Therapy Market

Autologous conditioned plasma therapy is used to treat a range of problems, such as musculoskeletal injuries, sports injuries and trauma. Today, among other things, it is widely used to treat skin ulcers, sports injuries, and cosmetic surgery. The growing demand for user-friendly treatment procedures is driving the expansion of the autologous conditioned plasma therapy market.

This procedure provides excellent and effective treatment without the need for painful surgery.

Autologous Conditioned Plasma Therapy Market contains market size and forecasts of Autologous Conditioned Plasma Therapy in Global, including the following market information:

Global Autologous Conditioned Plasma Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Autologous Conditioned Plasma Therapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Pure Platelet-Rich Plasma (P-PRP) Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Autologous Conditioned Plasma Therapy include Zimmer Biomet Inc., Terumo Corporation, AdiStem Ltd., Arthrex, Inc., Stryker Corporation, Cesca Therapeutics, Inc., Biotechnology Institute BTI, Dr. PRP America LLC and EmCyte Corporation, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Autologous Conditioned Plasma Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Autologous Conditioned Plasma Therapy Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Autologous Conditioned Plasma Therapy Market Segment Percentages, by Type, 2021 (%)

Pure Platelet-Rich Plasma (P-PRP)

Leukocyte- and Platelet-Rich Plasma (LPRP)

Pure Platelet-Rich Fibrin (P-PRF)

Leukocyte- and Platelet-Rich Fibrin (L-PRF)

Global Autologous Conditioned Plasma Therapy Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Autologous Conditioned Plasma Therapy Market Segment Percentages, by Application, 2021 (%)

Hospitals

Specialized Clinics

Ambulatory Surgical Centers

Orthopedic & Trauma Centers

Research Institutes

Global Autologous Conditioned Plasma Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Autologous Conditioned Plasma Therapy Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Autologous Conditioned Plasma Therapy revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Autologous Conditioned Plasma Therapy revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Zimmer Biomet Inc.

Terumo Corporation

AdiStem Ltd.

Arthrex, Inc.

Stryker Corporation

Cesca Therapeutics, Inc.

Biotechnology Institute BTI

Dr. PRP America LLC

EmCyte Corporation

Vivostat A/S

Regen Lab SA

Royal Biologics

Exactech, Inc.

Plateltex S.R.O.